

Electronic Supporting Information (ESI)

**Metal-free DBU promoted regioselective
synthesis of isoxazoles and isoxazolines[†]**

Shabber Mohammed,^{ab} Ram A. Vishwakarma,^{ab} and Sandip B. Bharate^{ab*}

*^aMedicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road,
Jammu-180001, India.*

*^bAcademy of Scientific & Innovative Research (AcSIR), CSIR-Indian Institute of Integrative
Medicine, Canal Road, Jammu-180001, India.*

**E-mail: sbharate@iiim.ac.in; sandipbharate@gmail.com*

Fax: +91-191-2569333; Tel: +91-191-2569000 (Extn. 345)

[†] IIIM Publication Number. IIIM/1723/2014

CONTENTS

Sr. No.	Section	Page no
S1.	Experimental procedures	S4
S2.	Spectral data of isoxazole/isoxazolines	S5-17
S3.	Scanned copies of ¹ H, ¹³ C and DEPT135 NMR spectra's of Isoxazole/ isoxazolines	S18
S3.1	¹ H, ¹³ C and DEPT135 NMR spectra of 4-(5-phenylisoxazol-3-yl)phenol (4a)	S18-19
S3.2	¹ H, ¹³ C and DEPT135 NMR spectra of spectra's of 3,5-diphenylisoxazole (4b)	S20
S3.3	¹ H, ¹³ C and DEPT135 NMR spectra of 3-(4-methoxyphenyl)-5-phenylisoxazole (4c)	S21-22
S3.4	¹ H, ¹³ C and DEPT135 NMR spectra of 5-phenyl-3-(p-tolyl)isoxazole (4d)	S23-24
S3.5	¹ H, ¹³ C and DEPT135 NMR spectra of 5-phenyl-3-(o-tolyl)isoxazole (4e)	S25-26
S3.6	¹ H, ¹³ C and DEPT135 NMR spectra of 4-(5-(4-(tert-butyl)phenyl)isoxazol-3-yl)phenol (4f)	S27-28
S3.7	¹ H, ¹³ C, and DEPT135 NMR spectra of 4-(5-(4-ethylphenyl)isoxazole-3-yl)phenol (4g)	S29-30
S3.8	¹ H, ¹³ C and DEPT135 NMR spectra of 1-((3-(p-tolyl) isoxazol-5-yl)methyl)indoline-2,3-dione (4h)	S31-32
S3.9	¹ H, ¹³ C and DEPT135 NMR spectra of 3-(3-(p-tolyl)isoxazole-5-yl)phenol (4i)	S33-34
S3.10	¹ H, ¹³ C and DEPT135 NMR spectra of 4-(5-(hydroxymethyl)isoxazole-3-yl)phenol (4j)	S35-36
S3.11	¹ H, ¹³ C and DEPT135 NMR spectra of 3-(1H-indol-3-yl)-5-phenylisoxazole (4k)	S37-38
S3.12	¹ H, ¹³ C and DEPT135 NMR spectra of 5-phenyl-3-(pyridine-2-yl) isoxazole (4l)	S39-40
S3.13	¹ H, ¹³ C, and DEPT135 spectra of 3,5-diphenyl-4,5-dihydroisoxazole (6a)	S41-42
S3.14	¹ H, ¹³ C, and DEPT135 spectra of 4-(5-(4-fluorophenyl)-4,5-dihydroisoxazol-3-yl)phenol (6b)	S43-44
S3.15	¹ H, ¹³ C and DEPT135 NMR spectra of 3-(2-ethoxyphenyl)-5-(4-fluorophenyl)-4,5-dihydroisoxazole (6c)	S45-46
S3.16	¹ H, ¹³ C and DEPT135 NMR spectra of 4-(5-phenyl-4,5-dihydroisoxazole-3-yl)phenol (6d)	S47-48
S3.17	¹ H, ¹³ C and DEPT135 NMR spectra of 3-(4-methoxyphenyl)-5-phenyl-4,5-dihydroisoxazole (6e)	S49
S3.18	¹ H, ¹³ C and DEPT135 NMR spectra of 5-phenyl-3-(p-tolyl)-4,5-dihydroisoxazole (6f)	S50-51
S3.19	¹ H, ¹³ C, and DEPT135 NMR spectra of 5-phenyl-3-(o-tolyl)-4,5-dihydroisoxazole (6g)	S52-53
S3.20	¹ H, ¹³ C, DEPT135 NMR spectra of 5-(3,4-dimethoxyphenyl)-3-phenyl-4,5-dihydroisoxazole (6h)	S54-55
S3.21	¹ H, ¹³ C and DEPT135 NMR spectra of 5-(3,4-dimethoxyphenyl)-3-(p-tolyl)-4,5-dihydroisoxazole (6i)	S56-57
S3.22	¹ H, ¹³ C and DEPT135 NMR spectra of 5-(4-fluorophenyl)-3-(4-methoxyphenyl)-4,5-	S58-59

	dihydroisoxazole (6j)	
S3.23	¹ H, ¹³ C and DEPT135 NMR spectra of 5-(4-fluorophenyl)-3-phenyl-4,5-dihydroisoxazole (6k)	S60-61
S3.24	¹ H, ¹³ C and DEPT135 NMR spectra of 5-(4-fluorophenyl)-3-(p-tolyl)-4,5-dihydroisoxazole (6l)	S62-63
S3.25	¹ H, ¹³ C and DEPT135 NMR spectra of 5-phenyl-3-(pyridine-2-yl)-4,5-dihydroisoxazole (6m)	S64-65
S3.26	¹ H, ¹³ C and DEPT135 NMR spectra of 5-(4-fluorophenyl)-3-(o-tolyl)-4,5-dihydroisoxazole (6n)	S66-67
S3.27	¹ H, ¹³ C and DEPT135 NMR spectra of 5-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)isoxazole (6o)	S68-69
S3.28	¹ H, ¹³ C and DEPT135 NMR spectra of 5-(3,4-dimethoxyphenyl)-3-(o-tolyl)-4,5-dihydroisoxazole (6p)	S70-71
S3.29	¹ H, ¹³ C and DEPT135 NMR spectra 3-(1H-indol-3yl)-5-phenyl-4,5-dihydroisoxazole (6q)	S72-73
S3.30	¹ H, ¹³ C and DEPT135 NMR spectra of 2-chloro-4-(5-phenylisoxazole-3-yl)phenol (7a)	S74-75
S3.31	¹ H, ¹³ C and DEPT135 NMR spectra of 2-chloro-4-(5-(p-tolyl)isoxazole-3-yl)phenol (7b)	S76-77
S3.32	¹ H, ¹³ C and DEPT135 NMR spectra of 2-chloro-4-(5-(4-ethylphenyl)isoxazole-3-yl)phenol (7c)	S78-79
S3.33	¹ H, ¹³ C and DEPT135 NMR spectra of 2-chloro-4-(5-phenylisoxazol-3-yl)phenol (7d)	S80-81
S3.34	¹ H, ¹³ C and DEPT135 NMR spectra of 2-chloro-4-(5-(4-fluorophenyl)-4,5-dihydroisoxazole-3yl)phenol (7e)	S82-83
S3.35	¹ H, ¹³ C and DEPT135 NMR spectra of 3-(5-chlorofuran-2-yl)-5-phenylisoxazole (7f)	S84-85
S3.36	¹ H, ¹³ C and DEPT135 NMR spectra of 3-(5-chlorofuran-2-yl)-5-phenyl-4,5-dihydroisoxazole (7g)	S86-87
S3.37.	¹ H, ¹³ C and DEPT135 NMR spectra of 3-(3-chloro-4-methoxyphenyl)-5-phenylisoxazole (7h)	S88-89
S4.	LC chart at different time intervals	S90-92
S5.	References associated with ESI	S93

S1. EXPERIMENTAL PROCEDURES

S1.a. General Information

All chemicals were obtained from Sigma-Aldrich Company and used as received. ¹H, ¹³C and DEPT NMR spectra were recorded on Bruker-Avance DPX FT-NMR 500 and 400 MHz instruments. Chemical data for protons are reported in parts per million (ppm) downfield from tetramethylsilane and are referenced to the residual proton in the NMR solvent (CDCl₃-7.26 and CD₃OD- 3.28 ppm). Carbon nuclear magnetic resonance spectra (¹³C NMR) were recorded at 125 MHz or 100 MHz: chemical data for carbons are reported in parts per million (ppm, δ scale) downfield from tetramethylsilane and are referenced to the carbon resonance of the solvent (CDCl₃-77 and CD₃OD-50 ppm). ESI-MS and HR-ESIMS spectra were recorded on Agilent 1100 LC-Q-TOF and HR-ESIMS-6540-UHD machines. IR spectra were recorded on Perkin-Elmer IR spectrophotometer. Melting points were recorded on digital melting point apparatus.

S1.b. General procedure for preparation of aldoximes


To the solution of hydroxylamine hydrochloride (1 g, 5.88 m mol) in water (5 ml) was added sodium hydroxide (307 mg, 0.5 m mol) and respective aldehydes (1 mmol) and reaction mixture was stirred for 2-3 hrs at room temperature. After completion of the reaction (monitoring by TLC), if compound precipitated out, was filtered on Buckner funnel or extracted with EtOAc (3 × 15 ml). The obtained product was taken for next step without further purification (> 90% yield).

S1.c. Optimized procedure for preparation of isoxazole and isoxazolines.

To the stirred solution of aldoximes (100 mg, 1 mmol) in DMF (3 ml) was added N-chlorosuccinimide (1.2 mmol) at room temperature and reaction was stirred for 0.5-1 h. Then, DBU (1 mmol) and alkynes/alkenes (1.2 mmol) were added and reaction was further stirred for 1-8 h. After completion of the reaction (confirmed by TLC), chilled water (20 ml) was added and product was extracted with EtOAc (3 × 10 ml). The organic layer was collected, dried on anhydrous sodium sulphate and solvent was evaporated on rotary evaporator to get the crude product. The crude product was purified by silica gel (#100-200) column chromatography using 2 to 20% EtOAc: hexane to get pure isoxazole/ isoxazoline products. For synthesis of chloro-substituted isoxazoles/ isoxazolines, similar procedure was used with the use of 2.2 mmol of NCS instead of 1.2 mmol.


S2. Spectral data of isoxazole and isoxazolines

S2.1. 4-(5-phenylisoxazol-3-yl) phenol (4a):¹




White solid; yield: 80%; m. p. 187-189 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.83 (dd, *J* = 4, 8 Hz, 2H), 7.76 (d, *J* = 8 Hz, 2H), 7.47 (m, 3H), 6.95 (d, *J* = 8 Hz, 2H), 6.78 (s, 1H); ¹³C NMR (CDCl₃ +CD₃OD, 125 MHz): δ 170.0, 162.9, 158.8, 130.2, 128.9, 128.2, 127.2, 125.7, 120.0, 115.7, 97.3; IR (CHCl₃): ν_{max} 3433, 2925, 1631, 1450, 1353, 1095, 1017 cm⁻¹; ESI-MS: *m/z* 238.08 [M+H]⁺; HR-ESIMS: *m/z* 238.0864 calcd for C₁₅H₁₁NO₂+H⁺ (238.0864).

S2.2. 3, 5-diphenylisoxazole (4b):²




White solid; yield: 75%; m. p. 140-142 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.86 (m, 4H), 7.49 (m, 6H), 6.84 (s, 1H); ¹³C NMR (CDCl₃, 125 MHz): δ 168.7, 161.3, 128.6, 128.4, 127.4, 127.3, 127.3, 125.8, 125.1, 124.2, 95.8; IR (CHCl₃): ν_{max} 3437, 3114, 2924, 1462, 1257, 1092, 763 cm⁻¹; ESI-MS: *m/z* 222.08 [M+H]⁺; HR-ESIMS: *m/z* 222.0917 calcd for C₁₅H₁₁NO+H⁺ (222.0913).

S2.3. 3-(4-Methoxyphenyl)-5-phenylisoxazole (4c):¹




White solid; yield: 72%; m. p. 114-117 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.80-7.85 (m, 4H), 7.43-7.51 (m, 3H), 6.99 (d, *J* = 8 Hz, 2H), 6.78 (s, 1H), 3.87 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ 170.1, 162.6, 161.0, 130.1, 129.0, 128.2, 127.5, 125.8, 121.6, 114.3, 97.2, 55.3; IR (CHCl₃): ν_{max} 3433, 2925, 1631, 1450, 1353, 1095, 1017 cm⁻¹; IR (CHCl₃): ν_{max} 3436, 2922, 2851, 1613, 1450, 1019, 841 cm⁻¹; ESI-MS: *m/z* 252.09 [M+H]⁺; HR-ESIMS: *m/z* 252.1021 calcd for C₁₆H₁₃NO₂+H⁺ (252.1019).

S2.4. 5-Phenyl-3-(p-tolyl)isoxazole (4d):³




White solid; yield: 88%; m.p. 110-112 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.82-7.84 (m, 2H), 7.76 (d, *J* = 8.0 Hz, 2H), 7.42-7.50 (m, 3H), 7.28 (d, *J* = 8.0 Hz, 2H), 6.80 (s, 1H), 2.41 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 170.1, 162.6, 161.0, 130.1, 129.0, 128.2, 127.5, 125.8, 121.6, 114.3, 97.2, 55.3; IR (CHCl₃): ν_{max} 3433, 2925, 1631, 1450, 1353, 1095, 1017 cm⁻¹; ESI-MS: *m/z* 236.10 [M+H]⁺; HR-ESIMS: *m/z* 236.1072 calcd for C₁₆H₁₃NO+H⁺ (236.1070).

S2.5. 5-Phenyl-3-(o-tolyl)isoxazole (4e):⁴




White liquid; yield: 87%; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.83 (d, *J* = 8.0 Hz, 1H), 7.66-7.68 (m, 2H), 7.39-7.46 (m, 4H), 7.30 (t, *J* = 8.0 Hz, 2H), 6.06 (s, 1H), 2.58 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 158.8, 138.9, 134.4, 131.5, 131.5, 130.1, 128.9, 128.3, 126.4, 126.0, 121.0, 113.0, 22.2; IR (CHCl₃): ν_{max} 3433, 2925, 1631, 1450, 1353, 1095, 1017 cm⁻¹; ESI-MS: *m/z* 236.10 [M+H]⁺; HR-ESIMS: *m/z* 236.1072 calcd for C₁₆H₁₃NO+H⁺ (236.1070).


S2.6. 4-(5-(4-(tert-butyl) phenyl) isoxazol-3-yl) phenol (4f)




White solid; yield 70%; m. p. 167-170 °C ; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.74-7.77 (m, 4H), 7.50 (d, *J* = 12.0 Hz, 2H), 6.95 (d, *J* = 8.0 Hz, 2H), 6.73(s, 1H), 1.27(s, 9H); ¹³C NMR (CDCl₃, 125 MHz): δ 170.3, 162.6, 157.4, 153.6, 128.4, 125.9, 125.6, 124.7, 121.5, 115.9, 96.8, 34.4, 31.20 IR (CHCl₃): ν_{max} 3351, 2963, 2868, 1614, 1435, 1269, 840 cm⁻¹; ESI-MS: *m/z* 294.14 [M+H]⁺; HR-ESIMS: *m/z* 294.1487 calcd for C₁₉H₁₉NO₂+H⁺ (294.1489).

S2.7. 4-(5-(4-Ethylphenyl) isoxazole-3-yl) phenol (4g)

White solid; yield: 70%; m. p. 172-174 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.77-7.78 (m, 4H), 7.32 (d, *J* = 8.0 Hz, 2H), 6.94 (d, *J* = 8.0 Hz, 2H), 6.73 (s, 1H), 2.71 (q, *J* = 8.0 Hz, 2H), 1.28 (t, *J* = 8.0 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 170.4, 162.6, 157.4, 146.8, 128.5, 128.4, 125.9, 124.9, 121.6, 115.9, 96.8, 28.8, 15.30; IR (CHCl₃): ν_{max} 3343, 2962, 2924, 1613, 1439, 1018, 838 cm⁻¹; ESI-MS: *m/z* 266.11 [M+H]⁺; HR-ESIMS: *m/z* 266.1183 calcd for C₁₇H₁₅NO₂+H⁺ (266.1176).

S2.8. 1-((3-(p-Tolyl) isoxazol-5-yl) methyl) indoline-2, 3-dione (4h)


Orange solid; yield: 50%; m. p. 167-169 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.62-7.66 (m, 4H), 7.24 (d, *J* = 8.0 Hz, 2H), 7.17 (t, *J* = 8.0 Hz, 1H), 7.09 (d, *J* = 8.0 Hz, 1H), 6.58 (s, 1H), 5.07 (s, 2H), 2.39 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 182.2, 165.7, 162.9, 157.7, 149.7, 140.6, 138.7, 129.7, 126.7, 125.7, 125.4, 124.4, 117.7, 110.7, 101.6, 35.5, 21.4 IR (CHCl₃): ν_{max} 3436, 2921, 1736, 1611, 1470, 1020 cm⁻¹; ESI-MS: *m/z* 319.11 [M+H]⁺.

S2.9. 3-(3-(p-Tolyl)isoxazole-5-yl)phenol (4i)

White solid; yield: 80%; m. p. 215-218 °C ; ¹H NMR (400 MHz, CD₃OD, ppm): δ 7.67 (d, *J* = 8.0 Hz, 2H), 7.21-7.25 (m, 5H), 7.01 (s, 1H), 6.81 (m, 1H), 2.31 (s, 3H); ¹³C NMR (CDCl₃+CD₃OD, 100 MHz): δ 169.7, 162.3, 156.7, 139.6, 129.4, 128.9, 127.6, 125.9, 125.1, 116.8, 116.5, 111.7, 96.9, 20.5; IR (CHCl₃): ν_{max} 3439, 3294, 2923, 2853, 1565, 1420, 1185, 686


cm⁻¹; ESI-MS: *m/z* 252.09 [M+H]⁺; HR-ESIMS: *m/z* 252.1017 calcd for C₁₆H₁₃NO₂+H⁺ (252.1019).

S2.10. 4-(5-(Hydroxymethyl) isoxazole-3-yl) phenol (4j):⁵




White solid; yield: 65%; m. p. 137-139 °C; ¹H NMR (400 MHz, CD₃OD, ppm): δ 7.56 (d, *J* = 8.0 Hz, 2H), 6.77 (d, *J* = 8.0 Hz, 2H), 6.50 (s, 1H), 4.59 (s, 2H); ¹³C NMR (CDCl₃+CD₃OD, 100 MHz): δ 179.2, 172.3, 162.2, 128.2, 120.0, 115.7, 99.5, 55.8; IR (CHCl₃): ν_{max} 3435, 2922, 2851, 1705, 1612, 1427, 1019 cm⁻¹; ESI-MS: *m/z* 192.06 [M+H]⁺; HR-ESIMS: *m/z* 192.0656 calcd for C₁₀H₉NO₃+H⁺ (192.0655).

S2.11. 3-(1H-Indol-3-yl)-5-phenylisoxazole (4k)



White solid; yield: 60%; m. p. 194-197 °C ; ¹H NMR (400 MHz, CD₃OD, ppm): δ 8.02-8.04 (m, 1H), 7.77-7.83 (m, 4H), 7.35-7.46 (m, 4H), 7.06-7.15(m, 3H); ¹³C NMR (CDCl₃+CD₃OD, 100 MHz): δ 169.0, 159.1, 136.5, 130.0, 128.9, 127.9, 125.9, 125.0, 124.9, 122.7, 121.0, 120.9, 111.5, 106.5, 97.7; IR (CHCl₃): ν_{max} 3301, 2922, 1595, 1580, 1441, 1106, 1019, 740 cm⁻¹; ESI-MS: *m/z* 261.09 [M+H]⁺; HR-ESIMS: *m/z* 261.1033 calcd for C₁₇H₁₂N₂O+H⁺ (261.1022).


S2.12. 5-Phenyl-3-(pyridine-2-yl)isoxazole (4l):⁶



White solid; yield: 78%; m. p. 79-81 °C ; ¹H NMR (400 MHz, CDCl₃, ppm): δ 8.72 (d, *J* = 8Hz, 1H), 8.14 (d, *J* = 8Hz, 1H), 7.80-7.88 (m, 3H), 7.46-7.52 (m, 3H), 7.38 (dd, *J* = 4, 8Hz, 1H), 7.21


(s, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ 170.6, 163.7, 149.7, 148.5, 136.9, 130.2, 129.0, 127.4, 125.8, 124.5, 121.6, 98.3; IR (CHCl_3): ν_{max} 3436, 2925, 1593, 1567, 1486, 1460, 1401, 764 cm^{-1} ; ESI-MS: m/z 223.08 $[\text{M}+\text{H}]^+$.

S2.13. 3, 5-Diphenyl-4, 5-dihydroisoxazole (6a):³




White solid; yield: 85%; m. p. 72-74 °C; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.70 (dd, $J = 4.0$, 8.0 Hz, 2H), 7.30- 7.42 (m, 8H), 5.75 (dd, $J = 11.0$, 8.3 Hz, 1H), 3.79(dd, $J = 16.6$, 11.0 Hz, 1H), 3.35 (dd, $J = 16.6$, 8.3 Hz, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ 156.1, 140.9, 130.2, 129.4, 128.8, 128.2, 126.7, 125.9, 82.6, 43.2; IR (CHCl_3): ν_{max} 3433, 2920, 1730, 1446, 1352, 1120, 893, 751, 686 cm^{-1} ; ESI-MS: m/z 224.10 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 224.1084 calcd for $\text{C}_{15}\text{H}_{13}\text{NO}+\text{H}^+$ (224.1070).

S2.14. 4-(5-(4-Fluorophenyl)-4, 5-dihydroisoxazol-3-yl)phenol (6b)




White solid; yield: 70%; m. p. 124 – 126 °C ; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.54 (d, $J = 8.0$ Hz, 2H), 7.36 (dd, $J = 4$, 8.0 Hz, 2H), 7.06 (t, $J = 8.0$ Hz, 2H), 6.86 (d, $J = 8.0$ Hz, 2H), 5.67(dd, $J = 10.4$, 8.6 Hz, 1H), 3.75 (dd, $J = 16.6$, 10.8 Hz, 1H), 3.28 (dd, $J = 16.6$, 8.2 Hz, 1H); ^{13}C NMR ($\text{CDCl}_3+\text{CD}_3\text{OD}$, 125 MHz): δ 162.5 (d, $^1J_{\text{CF}} = 245$ Hz), 159.0, 156.4, 136.6, 136.5, 128.4, 127.7, 127.6, 120.3, 115.6 (d, $^2J_{\text{CF}} = 21.2$ Hz), 115.5, 81.5, 43.4; IR (CHCl_3): ν_{max} 3405, 2921, 2852, 1538, 1493, 1272, 1017 cm^{-1} ; ESI-MS: m/z 258.11 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 258.0955 calcd for $\text{C}_{15}\text{H}_{12}\text{FNO}_2+\text{H}^+$ (258.0925).

S2.15. 3-(2-Ethoxyphenyl)-5-(4-fluorophenyl)-4,5-dihydroisoxazole (6c)




Colorless liquid; yield: 71%; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.79 (d, $J = 8.0$ Hz, 1H), 7.34- 7.40 (m, 3H), 7.06 (t, $J = 8.0$ Hz, 2H), 6.98 (t, $J = 8.0$ Hz, 1H), 6.91(d, $J = 8.0$ Hz, 1H), 5.66 (t, $J = 9.3$ Hz, 1H), 4.06 (q, $J = 6.9$ Hz, 2H), 3.90 (dd, $J = 17.4, 10.8$ Hz, 1H), 3.48 (dd, $J = 17.4, 8.1$ Hz, 1H), 1.39 (t, $J = 6.9$ Hz, 3H); ^{13}C NMR (CDCl_3 , 125 MHz): δ 162.5 (d, $^1J_{\text{CF}} = 245$ Hz), 156.9, 156.0, 137.1, 131.4, 129.4, 127.8, 127.7, 120.7, 118.6, 115.5 (d, $^2J_{\text{CF}} = 21.2$ Hz), 112.1, 81.9, 63.9, 45.8, 14.7; IR (CHCl_3): ν_{max} 3440, 2979, 2925, 1600, 1510, 1497, 1452, 1245, 1123, 1040 cm^{-1} ; ESI-MS: m/z 286.12 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 286.1260 calcd for $\text{C}_{17}\text{H}_{16}\text{FNO}_2+\text{H}^+$ (286.1238).

S2.16. 4-(5-phenyl-4, 5-dihydroisoxazole-3-yl) phenol (6d):⁷




White solid; yield: 72%; m. p. 140-142 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.59 (d, $J = 8.0$ Hz, 2H), 7.31- 7.41 (m, 5H), 6.86 (d, $J = 8.0$ Hz, 2H), 5.71 (dd, $J = 10.9, 8.3$ Hz, 1H), 3.75 (dd, $J = 16.5, 10.9$ Hz, 1H), 3.31 (dd, $J = 16.6, 8.2$ Hz, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ 156.9, 155.1, 139.7, 127.7, 127.5, 127.2, 124.8, 114.8, 81.2, 42.4; IR (CHCl_3): ν_{max} 3355, 2924, 2854, 1610, 1455, 1354, 1019, 836 cm^{-1} ; ESI-MS: m/z 240.11 $[\text{M}+\text{H}]^+$.

S2.17. 3-(4-Methoxyphenyl)-5-phenyl-4, 5-dihydroisoxazole (6e):²




White solid; yield: 70%; m. p. 95- 97 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.63 (d, $J = 12.0$ Hz, 2H), 7.33- 7.39 (m, 5H), 6.92 (d, $J = 12.0$ Hz, 2H), 5.71 (dd, $J = 10.9, 8.3$ Hz, 1H), 3.84 (s, 3H), 3.76(dd, $J = 16.5, 10.9$ Hz, 1H), 3.32 (dd, $J = 16.5, 8.2$ Hz, 1H); IR (CHCl_3): ν_{max} 3435, 2954, 2919, 2836, 1609, 1457, 1236, 1178, 1020, 829, 695 cm^{-1} ; ESI-MS: m/z 254.11 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 254.1176 calcd for $\text{C}_{16}\text{H}_{15}\text{NO}_2+\text{H}^+$ (254.1176).

S2.18. 5-Phenyl-3-(p-tolyl)-4,5-dihydroisoxazole (6f):³




White solid; yield: 82%; m. p. 94- 96 °C ; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.58 (d, $J = 8.0$, 2H), 7.31-7.41 (m, 5H), 7.21 (d, $J = 8.0$, 2H), 5.72 (dd, $J = 10.9$, 8.3 Hz, 1H), 3.76 (dd, $J = 16.4$, 8.3 Hz, 1H), 3.30 (dd, $J = 16.6$, 8.2 Hz, 1H), 2.38 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz): δ 156.1, 141.0, 140.4, 129.4, 128.7, 128.2, 126.7, 125.9, 82.4, 43.3, 21.4; IR (CHCl_3): ν_{max} 3439, 2923, 2853, 1456, 1430, 1238, 823 cm^{-1} ; ESI-MS: m/z 238.12 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 238.1228 calcd for $\text{C}_{16}\text{H}_{15}\text{NO}+\text{H}^+$ (238.1226).

S2.19. 5-phenyl-3-(*o*-tolyl)-4, 5-dihydroisoxazole (6g)




Colorless liquid; yield: 80%; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.21-7.42 (m, 9H), 5.69 (dd, $J = 10.7$, 8.1 Hz, 1H), 3.83 (dd, $J = 16.6$, 10.8 Hz, 1H), 3.39 (dd, $J = 16.6$, 8.0 Hz, 1H), 2.60 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz): δ 157.0, 141.1, 138.1, 131.6, 129.4, 128.8, 128.8, 128.5, 128.1, 125.8., 125.9, 82.4, 43.3, 21.4; IR (CHCl_3): ν_{max} 3435, 2923, 1587, 1494, 1454, 894 cm^{-1} ; ESI-MS: m/z 238.12 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 238.1235 calcd for $\text{C}_{16}\text{H}_{15}\text{NO}+\text{H}^+$ (238.1226).

S2.20. 5-(3, 4-Dimethoxyphenyl)-3-phenyl-4, 5-dihydroisoxazole (6h)




White solid; yield: 78%; m. p. 89-91 °C; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.69-7.72 (m, 2H), 7.41-7.43 (m, 3H), 6.93-6.94 (m, 2H), 6.86 (d, $J = 8\text{Hz}$, 1H), 5.70 (dd, $J = 10.7$, 8.9 Hz, 1H), 3.89 (s, 6H), 3.75 (dd, $J = 16.7$, 10.9 Hz, 1H), 3.35 (dd, $J = 16.7$, 8.8 Hz, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ 156.4, 149.2, 149.0, 133.1, 130.1, 129.5, 128.7, 118.5, 111.0, 108.9, 82.7, 55.9, 55.9, 43.0; IR (CHCl_3): ν_{max} 3435, 2924, 2851, 1593, 1516, 1261, 1025, cm^{-1} ; ESI-MS: m/z 284.12 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 284.1284 calcd for $\text{C}_{17}\text{H}_{17}\text{NO}_3+\text{H}^+$ (284.1281).

S2.21. 5-(3, 4-Dimethoxyphenyl)-3-(*p*-tolyl)-4, 5-dihydroisoxazole (6i)




White solid; yield: 80%; m. p. 84-87 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.59 (d, *J* = 8 Hz, 2H), 7.22 (d, *J* = 8 Hz, 2H), 6.93 (d, *J* = 8 Hz, 2H), 6.85 (d, *J* = 12 Hz, 1H), 5.67 (m, 1H), 3.88 (s, 6H), 3.72 (dd, *J* = 16.6, 10.8 Hz, 1H), 3.32 (dd, *J* = 16.6, 8.8 Hz, 1H), 2.39 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 156.3, 149.3, 140.3, 133.3, 129.4, 126.7, 126.6, 118.4, 111.1, 109.0, 82.5, 55.9, 55.9, 43.1, 21.4; IR (CHCl₃): ν_{max} 3439, 3294, 2924, 2836, 1517, 1454, 1261, 1138, 1026, 816 cm⁻¹; ESI-MS: *m/z* 298.14 [M+H]⁺; HR-ESIMS: *m/z* 298.1440 calcd for C₁₈H₁₉NO₃+H⁺ (298.1438).

S2.22. 5-(4-fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydroisoxazole (6j)




White solid; yield: 70%; m. p. 103-106 °C ; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.61-7.64 (m, 2H), 7.35-7.38 (m, 2H), 7.02-7.08 (m, 2H), 6.91-6.94 (m, 2H), 5.68 (dd, *J* = 10.8, 8.2 Hz, 1H) 3.84 (s, 3H), 3.74 (dd, *J* = 16.6, 10.9 Hz, 1H), 3.28 (dd, *J* = 16.6, 8.2 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz): δ 162.5 (d, ¹*J*_{CF} = 245 Hz), 161.1, 155.7, 136.8, 128.3, 127.7, 127.6, 121.8, 115.6 (d, ²*J*_{CF} = 23.2 Hz), 114.2, 81.6, 55.3, 43.4; IR CHCl₃): ν_{max} 3437, 2923, 2880, 1608, 1515, 1244, 1021, 831cm⁻¹; ESI-MS: *m/z* 272.10 [M+H]⁺; HR-ESIMS: *m/z* 272.1079 calcd for C₁₆H₁₄FNO₂+H⁺ (272.1081).

S2.23. 5-(4-Fluorophenyl)-3-phenyl-4,5-dihydroisoxazole (6k):⁸




White solid; yield: 82%; m. p. 87-89 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.69 (dd, *J* = 8.0, 4.0 Hz, 2H), 7.36-7.43 (m, 5H), 7.04-7.09 (m, 2H), 5.73 (dd, *J* = 11.0, 8.2 Hz, 1H), 3.78 (dd, *J* = 16.7, 11.0 Hz, 1H), 3.31 (dd, *J* = 16.7, 8.2 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz): δ 162.5 (d, ¹*J*_{CF} = 245 Hz), 156.5, 136.7, 136.7, 130.2, 128.8, 127.7, 127.6, 126.7, 115.6 (d, ²*J*_{CF} = 21.2 Hz), 81.9, 43.2; IR (CHCl₃): ν_{max} 3439, 2925, 2854, 1602, 1512, 1446, 1018, 830 cm⁻¹; ESI-MS: *m/z* 242.09 [M+H]⁺; HR-ESIMS: *m/z* 242.0982 calcd for C₁₅H₁₂FNO+H⁺ (242.0976).

S2.24. 5-(4-fluorophenyl)-3-(p-tolyl)-4,5-dihydroisoxazole (6l)




White solid; yield: 85%; m. p. 114-119 °C; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.58 (d, $J = 8.0$, 2H), 7.35-7.38 (m, 2H), 7.22 (d, $J = 8.0$, 2H), 7.06-7.08 (m, 2H), 5.70 (dd, $J = 10.8$, 8.2 Hz, 1H), 3.76 (dd, $J = 16.6$, 10.9 Hz, 1H), 3.29 (dd, $J = 16.6$, 8.2 Hz, 1H), 2.38 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz): δ 162.5 (d, $^1J_{\text{CF}} = 245$ Hz), 156.1, 140.5, 136.8, 129.5, 127.7, 127.7, 126.7, 126.5, 115.6 (d, $^2J_{\text{CF}} = 23.2$ Hz), 81.7, 43.3, 21.4; IR (CHCl_3): ν_{max} 3439, 2923, 2854, 1515, 1432, 1050, 823 cm^{-1} ; ESI-MS: m/z 256.11 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 256.1134 calcd for $\text{C}_{16}\text{H}_{14}\text{FNO}+\text{H}^+$ (256.1132).

S2.25. 5-phenyl-3-(pyridine-2-yl)-4,5-dihydroisoxazole (6m):⁹



Colourless liquid; yield: 80%; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 8.59-8.61 (m, 1H), 8.07 (d, $J = 8.0$, Hz, 1H), 7.72-7.76 (m, 1H), 7.28-7.42 (m, 6H), 5.80 (dd, $J = 10.6$, 8.0 Hz, 1H), 3.94 (dd, $J = 16.0$, 10.7 Hz, 1H), 3.55 (dd, $J = 16.0$, 8.0 Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz): δ 158.1, 149.3, 140.7, 136.4, 128.7, 128.2, 125.9, 124.3, 121.8, 83.3, 42.5; IR (CHCl_3): ν_{max} 3437, 2924, 2853, 1583, 1457, 1019, 772 cm^{-1} ; ESI-MS: m/z 225.09 $[\text{M}+\text{H}]^+$.


S2.26. 5-(4-Fluorophenyl)-3-(o-tolyl)-4,5-dihydroisoxazole (6n)



Colorless liquid; yield: 82%; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.33-7.40 (m, 2H), 7.29-7.31 (m, 3H), 7.21-7.25 (m, 1H), 7.07 (t, $J = 8.0$ Hz, 2H), 5.68 (dd, $J = 10.7$, 8.1 Hz, 1H), 3.82 (dd, $J = 16.6$, 10.8 Hz, 1H), 3.34 (dd, $J = 16.6$, 8.0 Hz, 1H), 2.59 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz): δ 162.5 (d, $^1J_{\text{CF}} = 245$ Hz), 157.0, 138.1, 136.8, 136.8, 131.6, 129.4, 128.8, 128.4, 127.6, 127.6, 125.8, δ 115.6 (d, $^2J_{\text{CF}} = 22$ Hz), 80.9, 45.7, 22.9; IR (CHCl_3): ν_{max} 3436, 2923, 1604, 1454,


1224, 1019 cm^{-1} ; ESI-MS: m/z 256.11 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 256.1132 calcd for $\text{C}_{16}\text{H}_{14}\text{FNO}+\text{H}^+$ (256.1132).

S2.27. 5-(3, 4-Dimethoxyphenyl)-3-(4-methoxyphenyl)isoxazole (6o)




White solid; yield: 72%; m. p. 96-99 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.63 (d, $J = 12.0$ Hz, 2H), 6.84-6.94 (m, 4H), 6.83 (d, $J = 8.0$ Hz, 1H), 5.65 (dd, $J = 10.6, 8.9$ Hz, 1H), 3.88 (s, 6H), 3.84 (s, 3H), 3.70 (dd, $J = 16.6, 10.8$ Hz, 1H), 3.31 (dd, $J = 16.6, 8.8$ Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz): δ 161.1, 155.9, 149.3, 149.0, 133.4, 128.2, 122.1, 118.4, 114.1, 111.1, 108.9, 82.3, 55.9, 55.9, 55.3, 43.3; IR (CHCl_3): ν_{max} 3439, 2929, 2837, 1607, 1516, 1257, 1024, 1024 cm^{-1} ; ESI-MS: m/z 314.13 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 314.1387 calcd for $\text{C}_{18}\text{H}_{19}\text{NO}_4+\text{H}^+$ (314.1387).

S2.28. 5-(3, 4-Dimethoxyphenyl)-3-(o-tolyl)-4, 5-dihydroisoxazole (6p)




Colorless liquid; yield: 78%; ^1H NMR (400 MHz, CDCl_3 , ppm): δ 7.23-7.35 (m, 4H), 6.92-6.95 (m, 2H), 6.86 (d, $J = 8\text{Hz}$, 1H), 5.65 (dd, $J = 10.6, 8.5$ Hz, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.79 (dd, $J = 16.6, 10.8$ Hz, 1H), 3.39 (dd, $J = 16.6, 8.4$ Hz, 1H), 2.60 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz): δ 157.2, 149.2, 148.9, 138.0, 133.3, 131.6, 129.4, 128.8, 128.5, 125.8, 118.3, 111.1, 108.8, 81.5, 55.9, 55.9, 45.6, 23.0; IR (CHCl_3): ν_{max} 3348, 2923, 1516, 1261, 1138, 1025, 759 cm^{-1} ; ESI-MS: m/z 298.14 $[\text{M}+\text{H}]^+$; HR-ESIMS: m/z 298.1453 calcd for $\text{C}_{18}\text{H}_{19}\text{NO}_3+\text{H}^+$ (298.1438).

S2.29. 3-(1H-Indol-3yl)-5-phenyl-4, 5-dihydroisoxazole (6q)




White solid; yield: 63%; m. p. 168-171 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 8.39 (s, 1-NH), 8.30 (d, *J* = 8.0, Hz, 1H), 7.25-7.45 (m, 9H), 5.67 (dd, *J* = 10.6, 8.0 Hz, 1H), 3.82 (dd, *J* = 16.0, 10.7 Hz, 1H), 3.38 (dd, *J* = 16.0, 8.0 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz): δ 152.4, 141.3, 136.5, 128.7, 128.0, 125.9, 125.8, 124.6, 123.6, 122.6, 121.5, 111.2, 107.7, 80.8, 44.6; IR (CHCl₃): ν_{max} 3414, 2922, 1595, 1433, 1019, 743 cm⁻¹; ESI-MS: *m/z* 263.11 [M+H]⁺; HR-ESIMS: *m/z* 263.1184 calcd for C₁₇H₁₄N₂O+H⁺ (263.1179).

S2.30. 2-Chloro-4-(5-phenylisoxazole-3-yl)phenol (7a)




White solid; yield: 88%; m.p. 193-196 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.89 (d, *J* = 4.1, Hz, 1H), 7.82-7.84 (m, 2H), 7.68-7.71 (m, 1H), 7.47-7.50 (m, 3H), 7.13 (d, *J* = 8 Hz, 1H), 6.77(s, 1H), 5.78 (s, 1H); ¹³C NMR (CDCl₃+CD₃OD, 125 MHz): δ 170.3, 161.9, 154.4, 130.3, 128.9, 128.3, 127.1, 126.3, 125.7, 121.0, 116.7, 97.2; IR (CHCl₃): ν_{max} 3346, 2922, 2851, 1594, 1422, 1019 cm⁻¹; ESI-MS: *m/z* 272.04 [M+H]⁺; HR-ESIMS: *m/z* 272.0481 calcd for C₁₅H₁₀ClNO₂+H⁺ (272.0473).

S2.31. 2-Chloro-4-(5-(p-tolyl)isoxazole-3-yl)phenol (7b)




White solid; yield: 86 %; m. p. 184-186 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.88 (d, *J* = 4.1, Hz, 1H), 7.73 (s, 1H), 7.67-7.71 (m, 2H), 7.29 (d, *J* = 8.0, Hz, 2H), 7.12 (d, *J* = 8.0, Hz, 1H), 6.71(s, 1H), 5.78 (s, 1H), 2.42(s, 3H); ¹³C NMR (CDCl₃+CD₃OD, 125 MHz): δ 170.5, 161.8, 154.3, 140.7, 129.6, 126.3, 125.6, 124.3, 121.3, 121.0, 116.7, 96.6, 21.32; IR (CHCl₃): ν_{max} 3128, 2922, 2851, 1602, 1425, 1300, 946, 779 cm⁻¹; ESI-MS: *m/z* 286.06 [M+H]⁺; HR-ESIMS: *m/z* 286.0630 calcd for C₁₆H₁₂ClNO₂+H⁺ (286.0629).

S2.32. 2-Chloro-4-(5-(4-ethylphenyl) isoxazole-3-yl) phenol (7c)




White solid; yield: 87%; m. p. 128-130 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.87 (d, *J* = 2.0 Hz, 1H), 7.74 (d, *J* = 8.2 Hz, 2H), 7.68 (dd, *J* = 8.5, 2.1 Hz, 1H), 7.31 (d, *J* = 8.2 Hz, 2H), 7.12 (d, *J* = 8.5 Hz, 1H), 6.71(s, 1H), 5.88 (s, OH), 2.71(q, *J* = 7.6 Hz, 2H), 1.28 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ 170.7, 161.5, 152.9, 146.9, 128.5, 127.6, 127.0, 125.9, 124.8, 122.7, 120.6, 116.7, 96.6, 28.8, 15.3; IR (CHCl₃): ν_{max} 3136, 2925, 2851, 1613, 1430, 1301, 1220, 1058 cm⁻¹; ESI-MS: *m/z* 300.07 [M+H]⁺; HR-ESIMS: *m/z* 300.0793 calcd for C₁₇H₁₄ClNO₂+H⁺ (300.0786).

S2.33. 2-Chloro-4-(5-phenyl-4,5-dihydroisoxazol-3-yl)phenol (7d)




White solid; yield: 90%; m. p. 140 – 142 °C ; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.68 (d, *J* = 1.9, Hz, 1H), 7.50(dd, *J* = 8.5, 1.9.0 Hz, 1H), 7.39-7.30 (m, 5H), 7.04 (d, *J* = 8.5 Hz, 1H), 6.22(s, OH), 5.73 (dd, *J* = 10.9, 8.3 Hz, 1H), 3.72(dd, *J* = 16.6, 11.0 Hz, 1H), 3.29 (dd, *J* = 16.6, 8.2 Hz, 1H); ¹³C NMR (CDCl₃+CD₃OD, 125 MHz): δ 155.5, 154.5, 140.5, 128.7, 128.4, 128.2, 126.4, 125.7, 121.6, 120.9, 116.6, 82.4, 43.1; IR (CHCl₃): ν_{max} 3344, 2919, 1603, 1510, 1338, 1292, 1206, 1057 cm⁻¹; ESI-MS: *m/z* 274.04 [M+H]⁺; HR-ESIMS: *m/z* 274.0639 calcd for C₁₅H₁₂ClNO₂+H⁺ (274.0629).

S2.34. 2-Chloro-4-(5-(4-fluorophenyl)-4,5-dihydroisoxazole-3-yl)phenol (7e)




White solid; yield: 92%; m. p. 180 – 182 °C ; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.69 (d, *J* = 1.9 Hz, 1H), 7.51 (dd, *J* = 8.5, 1.9 Hz, 1H), 7.35 (dd, *J* = 8.6, 5.3 Hz, 2H), 7.06 (t, *J* = 8.6, 3H), 5.80 (s, OH), 5.71 (dd, *J* = 10.8, 8.3 Hz, 1H), 3.72 (dd, *J* = 16.6, 10.9 Hz, 1H), 3.25 (dd, *J* = 16.6, 8.2 Hz, 1H); ¹³C NMR (CDCl₃+CD₃OD, 125 MHz): δ 161.5, 155.4, 154.6, 136.3, 128.4, 127.6, 127.5, 121.5, 120.9, 116.6, 115.6, 115.4, 81.7, 43.1; IR (CHCl₃): ν_{max} 3364, 2923, 2852, 1606, 1512, 1355, 1225, 834 cm⁻¹; ESI-MS: *m/z* 292.05 [M+H]⁺; HR-ESIMS: *m/z* 292.0563 calcd for C₁₅H₁₁ClFNO₂+H⁺ (292.0545).

S2.35. 3-(3-Chloro-4-methoxyphenyl)-5-phenylisoxazole (7f)




White solid; yield: 80%; m. p. 120-122 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 8.06 (d, *J* = 8.6 Hz, 2H), 7.86 (d, *J* = 8.6 Hz, 2H), 7.53 (m, 3H), 7.04(d, *J* = 8.6 Hz, 2H), 3.88(s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 163.9, 161.1, 160.3, 130.5, 129.6, 128.8, 128.7, 127.4, 126.6, 126.5, 119.8, 114.2, 104.4, 55.3; IR (CHCl₃): ν_{max} 3344, 2919, 1603, 1510, 1338, 1292, 1206, 1057 cm⁻¹; ESI-MS: *m/z* 286.06 [M+H]⁺, HR-ESIMS: *m/z* 286.0632 calcd for C₁₆H₁₂ClNO₂+H⁺ (286.0629).

S2.36. 3-(5-Chlorofuran-2-yl)-5-phenylisoxazole (7g)



White solid; yield: 90%; m. p. 115-117 °C ; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.82 (dd, *J* = 7.6, 1.7 Hz, 2H), 7.56-7.44 (m, 3H), 6.95 (d, *J* = 3.5 Hz, 1H), 6.77(s, 1H), 6.33(d, *J* = 3.4, Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz): δ 170.4, 154.6, 143.9, 138.3, 130.4, 129.0, 125.9, 112.04, 108.5, 96.7; IR (CHCl₃): ν_{max} 3437, 3126, 2921, 1521, 1418, 1018, 759 cm⁻¹; ESI-MS: *m/z* 246.02 [M+H]⁺; HR-ESIMS: *m/z* 246.0314 calcd for C₁₃H₈ClNO₂+H⁺ (246.0316).



S2.37. 3-(5-chlorofuran-2-yl)-5-phenyl-4, 5-dihydroisoxazole (7h)




White solid; yield: 60%; m. p. 99- 101 °C; ¹H NMR (400 MHz, CDCl₃, ppm): δ 7.30-7.40 (m, 5H), 6.72 (d, *J* = 3.5 Hz, 1H), 6.27 (d, *J* = 3.5 Hz, 1H) 5.71(dd, *J* = 10.9, 8.2 Hz, 1H), 3.71(dd, *J* = 16.7, 11.0 Hz, 1H), 3.27(dd, *J* = 16.7, 8.2 Hz, 1H), ¹³C NMR (CDCl₃, 125 MHz): δ 147.7, 144.2, 140.2, 138.9, 128.8, 128.4, 125.8, 113.7, 108.6, 82.4, 42.6; IR (CHCl₃): ν_{max} 3436, 2922, 1618, 1433, 1017cm⁻¹; ESI-MS: *m/z* 248.04 [M+H]⁺; HR-ESIMS: *m/z* 248.0480 calcd for C₁₃H₁₀ClNO₂+H⁺ (248.0473).

S3. Scanned copies of ^1H , ^{13}C and DEPT135 NMR spectra's of isoxazoles/ isoxazolines



S3.1. ^1H , ^{13}C and DEPT135 NMR spectra of 4-(5-phenylisoxazol-3-yl) phenol (**4a**)





19-jun-c13-shabbir
SS-402A





S3.2. ^1H , and ^{13}C NMR spectra's of spectra's of 3,5-diphenylisoxazole (**4b**)





S3.3. ^1H , ^{13}C and DEPT135 NMR spectra of 3-(4-methoxyphenyl)-5-phenylisoxazole (**4c**)



c13-shabbir
SS-693



S3.4. ^1H , ^{13}C and DEPT135 NMR spectra of 5-phenyl-3-(p-tolyl)isoxazole (**4d**)





c13-shabbir
SS-696



130.17
129.65
129.01
128.84


97.46

21.45





S3.5. ^1H , ^{13}C and DEPT135 NMR spectra of 5-phenyl-3-(o-tolyl)isoxazole (**4e**)









S3.6. ^1H , ^{13}C and DEPT135 NMR spectra of 4-(5-(4-(tert-butyl) phenyl) isoxazol-3-yl) phenol (**4f**)





c13-shabbir
SS-623





S3.7. ^1H , ^{13}C and DEPT135 NMR spectra of 4-(5-(4-ethylphenyl) isoxazole-3-yl) phenol (**4g**)





c13-msudhakar
SS-624





S3.8. ^1H , ^{13}C and DEPT135 NMR spectra of 3-((3-(p-tolyl) isoxazole-5yl) methyl)-1H-indene-1,2(3H)-dione (**4h**)





c13-rammohan
SS-647





S3.9. ^1H , ^{13}C and DEPT135 NMR spectra of 3-(3-(p-tolyl) isoxazole-5-yl) phenol (**4i**)





15-july-c13-shabeer
SS-651





S3.10. ^1H , ^{13}C and DEPT135 NMR spectra of 4-(5-(hydroxymethyl) isoxazole-3-yl) phenol (**4j**)





c13-shabeer
SS-502





S3.11. ^1H , ^{13}C and DEPT135 NMR spectra of 3-(1H-indol-3-yl)-5-phenylisoxazole (**4k**)





c13-shabeer
SS-667





S3.12, ¹H, ¹³C and DEPT135 NMR spectra of 5-phenyl-3-(pyridine-2-yl) isoxazole (41)





21-may-c13-shabeer
SS-672





S3.13. ^1H , ^{13}C , and DEPT135 spectra of 3,5-diphenyl-4,5-dihydroisoxazole (**6a**)





21-ap-c13-shabbir
SS-632





S3.14. ^1H , ^{13}C , and DEPT135 spectra of 4-(5-(4-fluorophenyl)-4, 5-dihydroisoxazol-3-yl) phenol (**6b**)





c13-shabeer
SS-438B





S3.15. ^1H , ^{13}C , and DEPT135 spectra of 3-(2-ethoxyphenyl)-5-(4-fluorophenyl)-4,5-dihydroisoxazole (**6c**)





24-apr-c13-shabbir
SS-440




S3.16. ^1H , ^{13}C , and DEPT135 spectra of 4-(5-phenyl-4, 5-dihydroisoxazole-3-yl) phenol (**6d**)





SS-456B-C13
SS-456B





S3.17. ^1H , ^{13}C and DEPT135 NMR spectra of 3-(4-methoxyphenyl)-5-phenyl-4,5-dihydroisoxazole (**6e**)





S3.18. ^1H , ^{13}C and DEPT135 NMR spectra of 5-phenyl-3-(p-tolyl)-4,5-dihydroisoxazole (**6f**)





24-apr-c13-shabbir
SS-633





S3.19. ^1H , ^{13}C , and DEPT135 NMR spectra of 5-phenyl-3-(o-tolyl)-4, 5-dihydroisoxazole (**6g**)





c13-jaideep
SS-634





S3.20. ^1H , ^{13}C , and DEPT135 NMR spectra of 5-(3, 4-dimethoxyphenyl)-3-phenyl-4,5-dihydroisoxazole (6h)





c13-shabbir
SS-635





S3.21. ¹H, ¹³C and DEPT135 NMR spectra of 5-(3,4-dimethoxyphenyl)-3-(p-tolyl)-4,5-dihydroisoxazole (6i)



c13-shabbir
SS-636



S3.22. ^1H , ^{13}C and DEPT135 NMR spectra of 5-(4-fluorophenyl)-3-(4-methoxyphenyl)-4, 5-dihydroisoxazole (6j)





c13-shabber
SS-656

128.31
127.74
127.67



115.73
115.56
114.20

81.67



55.39





S3.23. ^1H , ^{13}C and DEPT135 NMR spectra of 5-(4-fluorophenyl)-3-phenyl-4,5-dihydroisoxazole (**6k**)





c13-rammohan
SS-644





S3.24. ^1H , ^{13}C and DEPT135 NMR spectra of 5-(4-fluorophenyl)-3-(p-tolyl)-4, 5-dihydroisoxazole (**6l**)





c13-shabeer
SS-639





S3.25. ^1H , ^{13}C and DEPT135 NMR spectra of 5-phenyl-3-(pyridine-2-yl)-4, 5-dihydroisoxazole (**6m**)





21-may-c13-shabeer
SS-673





S3.26. ^1H , ^{13}C and DEPT135 NMR spectra of 5-(4-fluorophenyl)-3-(o-tolyl)-4, 5-dihydroisoxazole (**6n**)





c13-shabbir
SS-630




S3.27. ^1H , ^{13}C and DEPT135 NMR spectra of 5-(3, 4-dimethoxyphenyl)-3-(4-methoxyphenyl) isoxazole (60)




c13-rohit
SS-655



S3.28. ^1H , ^{13}C and DEPT135 NMR spectra of 5-(3, 4-dimethoxyphenyl)-3-(o-tolyl)-4,5-dihydroisoxazole (6p)



SS-637-c13
SS-637




131.64
128.41
128.85
128.86
118.33
111.10
108.81



81.57

55.98
55.94



23.06




S3.29. ^1H , ^{13}C and DEPT135 NMR spectra of 3-(1H-indol-3-yl)-5-phenyl-4, 5-dihydroisoxazole (**6q**)



c13-shabeer
SS-678





S3.30. ^1H , ^{13}C and DEPT135 NMR spectra of 2-chloro-4-(5-phenylisoxazole-3-yl) phenol (**7a**)





16-may-c13-shabbir
SS-660



130.30
128.94
128.35
126.31
125.70
116.77
97.20




S3.31. ^1H , ^{13}C and DEPT135 NMR spectra of 2-chloro-4-(5-(p-tolyl) isoxazole-3-yl)phenol (**7b**)





c13-shabeer
SS-661





S3.32. ^1H , ^{13}C and DEPT135 NMR spectra of 2-chloro-4-(5-(4-ethylphenyl) isoxazole-3-yl) phenol (**7c**)









S3.33. ^1H , ^{13}C and DEPT135 NMR spectra of 2-chloro-4-(5-phenylisoxazol-3-yl) phenol (**7d**)





c13-shabeer
SS-694





S3. 34. ^1H , ^{13}C and DEPT135 NMR spectra of 2-chloro-4-(5-(4-fluorophenyl)-4,5-dihydroisoxazole-3yl)phenol (**7e**)



c13-rammohan
SS-469





S3. 35. ^1H , ^{13}C and DEPT135 NMR spectra of 3-(5-chlorofuran-2-yl)-5-phenylisoxazole (**7f**)




27-may-c13-shabbir
SS-663


130.48
129.05
125.91
112.04
106.52
96.74




S3. 36. ^1H , ^{13}C and DEPT135 NMR spectra of 3-(5-chlorofuran-2-yl)-5-phenyl-4,5-dihydroisoxazole (7g)





c13-shabeer
SS-676





c13-shabeer
SS-676



S3. 37. ^1H , ^{13}C and DEPT135 NMR spectra of 3-(3-chloro-4-methoxyphenyl)-5-phenylisoxazole (**7h**)



c13-shabbir
SS-712



S4. LCMS chromatogram at different time intervals.

LC-ESI-MS/MS analysis was carried out on Agilent Triple-Quad LC-MS/MS system (model 6410). Liquid chromatography analyses were carried out using an Agilent 1260 Infinity (Agilent, USA) quaternary pump equipped with an autosampler, column heater and online degasser. A Chromolith C₁₈ (Merck, Germany) column (55 x 4.6 mm) was used at 30 °C temperature and the injection volume was 10 µl. The elution was carried out with binary solvent system consisting of 0.1% formic acid in water (solvent A) and acetonitrile (solvent B) at a constant flow-rate of 0.5 ml/min. The gradient elution was used, as depicted in Table S4-a.

Table S4-a. Gradient details used in LC-ESI-MS/MS analysis


Time	Solvent A (water – 0.1% formic acid)	Solvent B (acetonitrile)	Flow rate (ml/min)
0	80	20	0.5
8	40	60	0.5
15	40	60	0.5
17	80	20	0.5
20	80	20	0.5










Other instrument parameters are listed in Table S4-b.

Table S4-b. Instrument parameters during LC-ESI-MS/MS analysis

Source parameters		Autosampler parameters		Quaternary pump parameters	
Gas Temp.	300 °C	Injection volume	10 µl	Run time	15 min
Gas flow	8 L/min	Eject speed	200 µl/min	Flow rate	0.5 ml/min
Nebulizer pressure	50 psi	Draw speed	200 µl/min	Elution	Gradient*
Capillary voltage	3000 v				
Cell Acc (v)	7 v				

* Gradient system is provided in Table S4-a





S5. References associated with ESI

1. M. A. Weidner-Wells, T. C. Henninger, S. A. Fraga-Spano, C. M. Boggs, M. Matheis, D. M. Ritchie, D. C. Argentieri, M. P. Wachter and D. J. Hlasta, *Bioorg. Med. Chem. Lett.* 2004, **14**, 4307–4311.
2. S. Minakata, S. Okumura, T. Nagamachi and Y. Takeda, *Org. Lett.* 2011, **13**, 2966-2969.
3. A. Yoshimura, K. R. Middleton, A. D. Todora, B. J. Kastern, S. R. Koski, A. V. Maskaev and V. V. Zhdankin, *Org. Lett.* 2013, **15**, 4010-4013.
4. R. Harris and J. Huppertz, *Aust. J. Chem.* 1977, **30**, 2225-2240.
5. C. Shen, Y. Zhang, Y. Gan, T. Zhao and Q. Gu, *Lett. Org. Chem.* 2011, **8**, 278-281.
6. S. Tang, J. He, Y. Sun, L. He and X. She, *Org. Lett.* 2009, **11**, 3982-3985.
7. M. Boruah and D. Konwar, *Synth. Commun.* 2012, **42**, 3261-3268.
8. A. Yoshimura, C. Zhu, K. R. Middleton, A. D. Todora, B. J. Kastern, A. V. Maskaev and V. V. Zhdankin, *Chem. Commun.* 2013, **49**, 4800-4802.
9. S. Kanemasa, H. Matsuda, A. Kamimura and T. Kakinami, *Tetrahedron* 2000, **56**, 1057-1064.